StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
AstraZeneca's (AZN) Phase III FALCON Trial of Fulvestrant vs. Anastrozole Met Primary Endpoint
May 27, 2016 7:08 AM
AstraZeneca (NYSE: AZN) announced positive results from the Phase III FALCON trial comparing fulvestrant 500mg to anastrozole 1mg for the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
AstraZeneca's Fulvestrant Met Its Primary Endpoint as First-Line Treatment in a Phase III Trial for HR+ Advanced Breast Cancer
May 27, 2016 7:00 AM
Relypsa (RLYP) Surges Higher After AstraZeneca's ZS-9 Receives CRL from FDA
May 27, 2016 6:18 AM
AstraZeneca (AZN) Receives CRL on ZS-9
May 27, 2016 6:14 AM
Relypsa (RLYP) Ticks Higher Ahead of FDA on ZS-9
May 26, 2016 4:38 PM
Relypsa (RLYP) Gains Ahead of Binary Event
May 25, 2016 11:04 AM
Medivation's (MDVN) Board Split Over Support for Gilead (GILD), Pfizer (PFE) Proposals - Source
May 25, 2016 10:00 AM
French drugmaker Sanofi to step up push into China
May 25, 2016 5:05 AM
